Clinical trial
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting…
NCT00292266 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00292266 |
|---|---|
| Title | A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) |
| Official title | An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif® 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex® 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Merck Serono International SA Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Rebif®, Avonex® |
| Enrollment | 677 |
| Start date | Nov 1, 1999 |
| Primary completion | Jun 1, 2002 |
| Completion | Jun 1, 2002 |
| First posted | Feb 15, 2006 |
| Last update posted | Aug 5, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: